Back

Healthcare City Innovation & Commitment in a Time of Crisis

Share Page

Johnson & Johnson, headquartered in New Brunswick, NJ,  has been actively engaged in fighting pandemics for over a century.

With the onset of the COVID-19 pandemic in 2020, over 130,000 Johnson & Johnson employees in New Brunswick and around the world mobilized with urgency to address the critical needs of families, communities and healthcare providers.

On Feb. 27, 2021 Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older.

This decision was based on scientific evidence that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.

"This milestone follows a year of incredible work by our dedicated teams and unprecedented collaboration with health leaders around the world – all of whom shared a goal of bringing a single-shot vaccine to the public," said Alex Gorsky, Chairman and Chief Executive Officer at Johnson & Johnson. "We will do everything we can to help bring this pandemic to an end, in the United States and throughout the world."

Johnson & Johnson is committed to making its COVID-19 vaccine available on a not-for-profit basis for emergency pandemic use. Shipments of the COVID-19 vaccines have begun and Johnson & Johnson expects to deliver enough single-shot vaccines by the end of March to enable the full vaccination of more than 20 million people in the U.S. The Company plans to deliver 100 million single-shot vaccines to the U.S. during the first half of 2021.

For all the latest news on Johnson & Johnson’s COVID-19 response efforts, visit http://www.jnj.com/coronavirus.

Additional COVID-19 Resources

Visit New Jersey’s COVID-19 Vaccine Registration site to pre-register for the vaccine. New Jersey's COVID-19 Vaccine Appointment Call Center can be reached at 855-568-0545.

Download the COVID Alert NJ mobile app to receive up-to-date information regarding reopening’s, key COVID-19 data, and contact alerts. The app is free and secure, and user information will remain anonymous.